Boothbay Fund Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.29M Buy
+116,700
New +$5.53M 0.06% 360
2025
Q4
Sell
-54,600
Closed -$3.03M 2242
2025
Q3
$3.03M Buy
+54,600
New +$3.2M 0.04% 453
2023
Q2
Sell
-71,400
Closed -$5.68M 2141
2023
Q1
$5.68M Buy
+71,400
New +$5.06M 0.12% 214

Other funds holding NVO

Boothbay Fund Management's NVO Position: Q1 2026 in Review

Boothbay Fund Management increased its Novo Nordisk (NVO) stake by 40% in Q1 2026, buying an estimated $383K and bringing the position to 28,120 shares worth $1.03M. The position accounts for 0.01% of the portfolio, ranked #930.

Boothbay Fund Management first reported a position in NVO in Q1 2020 and has held it in 20 quarters since. The position peaked at $8.28M in Q2 2022. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Boothbay Fund Management held 28,120 shares of Novo Nordisk worth $1.03M as of Q1 2026.
  • Boothbay Fund Management bought 8,077 Novo Nordisk shares in Q1 2026, an estimated $383K.
  • Novo Nordisk made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #930 holding.
  • Boothbay Fund Management first reported a position in Novo Nordisk in Q1 2020 and has held it in 20 quarters since.
  • Boothbay Fund Management's Novo Nordisk position peaked at $8.28M in Q2 2022.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.